

[Cloxacillin](#)

Statut de médicament essentiel

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics](#)

Codes ATC: [J01CF02](#)

EMLc

Indication

Sepsis without septic shock Code ICD11: [1G40](#)

INN

Cloxacillin

Type de médicament

Chemical agent

Groupes d'antibiotiques

[ACCESS](#)

Type de liste

Liste de base

Additional notes

*cloxacillin, dicloxacillin and flucloxacillin are preferred for oral administration due to better bioavailability

Formulations

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid (EMLc) ; 250 mg per 5 mL (as sodium salt) powder for oral liquid (EMLc)

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection (EMLc) ; 250 mg in vial (as sodium salt) powder for injection (EMLc)

Oral > Solid > capsule: 500 mg (as sodium salt) (EMLc) ; 1 g (as sodium salt) (EMLc) ; 250 mg (as sodium salt) (EMLc)

Historique des statuts LME

Ajouté pour la première fois en 2017 ([TRS 1006](#))

Modifié en 2021 ([TRS 1035](#))

Modifié en 2023 ([TRS 1049](#))

Sexe

Tous

Âge

Enfants (1 mois - 12 ans)

Équivalence thérapeutique

[dicloxacillin](#) (Codes ATC: [J01CF01](#))

[meticcillin](#) (Codes ATC: [J01CF03](#))

[oxacillin](#) (Codes ATC: [J01CF04](#))

[flucloxacillin](#) (Codes ATC: [J01CF05](#))

[nafcillin](#) (Codes ATC: [J01CF06](#))

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Wikipédia

[Cloxacillin](#)

DrugBank

[Cloxacillin](#)

Recommandation du comité d'experts



In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as sulfate) in 2 mL vial) to the EMLc. - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of new strength formulations of cloxacillin (capsule 250 mg, powder for injection 250 mg (as sodium) and powder for oral liquid 250 mg/5 mL (as sodium) on the EMLc.

Recommandations de la LME : Sepsis without septic shock

Premier choix

Second choix

Premier choix

[gentamicin](#)

[gentamicin](#)

[gentamicin](#)

Second choix

[cefotaxime](#)

[ceftriaxone](#)

[cloxacillin](#)